SynthesisPloS one2014
Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions: A Meta-Analysis.JAMA network open · 2024Pooled it
- A noninferiority randomized open-label pilot study of 3- versus 7-day influenza postexposure prophylaxis with oseltamivir in hospitalized children.Scientific reports · 2024Trial
- Article
- Seasonal Influenza in Children With Cancer.Cureus · 2024Review
- Characteristics and determinants of seasonal influenza vaccination in Manitoba, Canada: A population-wide record-linkage study.Vaccine: X · 2024Article
- The Impact of Coronavirus Disease 2019 on Viral, Bacterial, and Fungal Respiratory Infections.Clinics in chest medicine · 2023Review
- Comparison of Intra-Familial Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Oseltamivir Using an Influenza Transmission Model and a Health Insurance Claims Database.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- System dynamic modelling of healthcare associated influenza -a tool for infection control.BMC health services research · 2022Article
- Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Influenza Management During the COVID-19 Pandemic: A Review of Recent Innovations in Antiviral Therapy and Relevance to Primary Care Practice.Mayo Clinic proceedings. Innovations, quality & outcomes · 2021Review
- Divergent Mast Cell Responses Modulate Antiviral Immunity During Influenza Virus Infection.Frontiers in cellular and infection microbiology · 2021Review
- Five-Day vs 10-Day Postexposure Chemoprophylaxis With Oseltamivir to Prevent Hospital Transmission of Influenza: A Noninferiority Randomized Open-Label Study.Open forum infectious diseases · 2020Article
- COVID-19: Time for Post-Exposure Prophylaxis?International journal of environmental research and public health · 2020Review
- Academic Life in Emergency Medicine (ALiEM) Blog and Podcast Watch: Infectious Diseases.Cureus · 2020Review
- Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.Influenza and other respiratory viruses · 2019Observational
- Improving preparedness for the next flu pandemic.Nature microbiology · 2018Article
- Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALICBMJ open · 2018Article
- Treating Influenza Infection, From Now and Into the Future.Frontiers in immunology · 2018Review
- The Effectiveness of Trivalent Inactivated Influenza Vaccine in Children with Acute Leukemia.The Journal of pediatrics · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the effectiveness of neuraminidase inhibitors for use in rapid containment of influenza.
methodWe conducted a systematic review and meta-analysis in accordance with the PRISMA statement. Healthcare databases and sources of grey literature were searched up to 2012 and records screened against protocol eligibility criteria. Data extraction and risk of bias assessments were performed using a piloted form. Results were synthesised narratively and we undertook meta-analyses to calculate pooled estimates of effect, statistical heterogeneity and assessed publication bias.
findingsNine randomised controlled trials (RCTs) and eight observational studies met the inclusion criteria. Neuraminidase inhibitors provided 67 to 89% protection for individuals following prophylaxis. Meta-analysis of individual protection showed a significantly lower pooled odds of laboratory confirmed seasonal or influenza A(H1N1)pdm09 infection following oseltamivir usage compared to placebo or no therapy (n = 8 studies; odds ratio (OR) = 0.11; 95% confidence interval (CI) = 0.06 to 0.20; p<0.001; I2 = 58.7%). This result was comparable to the pooled odds ratio for individual protection with zanamivir (OR = 0.23; 95% CI 0.16 to 0.35). Similar point estimates were obtained with widely overlapping 95% CIs for household protection with oseltamivir or zanamivir. We found no studies of neuraminidase inhibitors to prevent population-wide community transmission of influenza.
conclusionOseltamivir and zanamivir are effective for prophylaxis of individuals and households irrespective of treatment of the index case. There are no data which directly support an effect on wider community transmission. PROTOCOL REGISTRY: PROSPERO registration number: CRD42013003880.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.